We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
David Rubin

David T. Rubin MD, FACG, AGAF, FACP

Professor of Medicine; Chief of Gastroenterology, Hepatology & Nutrition; Co-Director, Inflammatory Bowel Disease Center, The University of Chicago Medicine, Chicago, Illinois

Dr. David T. Rubin is the Joseph B. Kirsner Professor of Medicine, Chief of the Section of Gastroenterology, Hepatology & Nutrition and the Co-Director of the Digestive Diseases Center at The University of Chicago Medicine. Dr. Rubin earned a medical degree with honors at The University of Chicago Pritzker School of Medicine. He completed his residency in internal medicine and fellowships in gastroenterology and clinical medical ethics at the University of Chicago, where he served as Chief Resident and Chief Fellow. Prior to his current appointments, Dr. Rubin served for 11 years as Director of the Gastroenterology, Hepatology and Nutrition fellowship program. He also currently serves as an associate faculty member at the MacLean Center for Clinical Medical Ethics and an associate investigator at the University of Chicago Comprehensive Cancer Center.

Dr. Rubin is a Fellow of the American Gastroenterological Association (AGA), the American College of Gastroenterology (ACG), the American Society for Gastrointestinal Endoscopy (ASGE) and the American College of Physicians (ACP) and an active national member of the Crohn’s & Colitis Foundation, and is on the Board of Trustees for the ACG. Among numerous awards and honors, Dr. Rubin was chosen by his peers as a member of Best Doctors (recognized for superior clinical ability) and America’s Top Physicians (gastroenterology). Additionally, he twice received the ACG’s Governor’s Award of Excellence in Clinical Research (2003 and 2013), the Cancer Research Foundation Young Investigator’s Award (2004), and the UC Postgraduate Teaching Award in recognition of significant contributions for fellowship education (2006). In 2012, he received the CCF Rosenthal Award, a national leadership award bestowed upon a volunteer who has contributed in an indisputable way to the quality of life of patients and families. He is currently the Chair-elect of the National Scientific Advisory Committee of the Crohn’s and Colitis Foundation. He is an Associate Editor of the journal Gastroenterology and Editor of the ACG On-Line Educational Universe.

Dr. Rubin is the editor of a best-selling book on inflammatory bowel disease (IBD), now in its 3rd edition, an associate editor of the 11th edition of Sleisenger and Fordtran’s Gastrointestinal and Liver Disease, and an author or coauthor of many peer-reviewed articles on treatment and management of IBD, cancer in IBD and novel paradigms, as well as the first author of the in progress ACG Guidelines for ulcerative colitis. His current research is in the area of progressive complications from uncontrolled inflammation, the doctor-patient relationship in IBD, and a variety of collaborative studies related to the microbiome and intestinal disease. He is also a featured media contact for issues related to IBD, appearing on satellite radio, television, print media and maintains a popular twitter feed @IBDMD (>11,000 followers). His principal research interests include novel IBD therapies and outcomes, colon cancer prevention, and clinical medical ethics.

Disclosures

Dr. Rubin is a consultant for Abbvie, Abgenomics, Allergan, Inc., Biomica, Boehringer Ingelheim, Ltd., Bristol-Myers Squibb, Celgene Corp/Syneos, Check-cap, Dizal Pharmaceuticals, GalenPharma/Atlantica, Genentech/Roche, Gilead Sciences, Ichnos Sciences S.A. (formerly Glenmark Pharmaceuticals), GSK (GlaxoSmithKline Group), Janssen Pharmaceuticals, Lilly, Narrow River Mgmt, Pfizer, Prometheus Laboratories, Reistone, Shire, Takeda, and Techlab, Inc. He receives grant support from Abbvie, Genentech/Roche, Janssen Pharmaceuticals, Prometheus Laboratories, Shire, and Takeda.

Dr. Rubin has stock options with Abgenomics and Biomica. He is co-founder and CFO of Cornerstones Health, Inc. (non-profit), and is co-founder of GoDuRn, LLC.

Dr. Rubin is on the Board of Trustees of the American College of Gastroenterology.